Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus

•The rH7 was expressed successfully in glycoengineered Pichia pastoris system.•The rH7 had complex glycosylation modifications and polymerized to nanoparticles.•The 3.75 µg rH7 was found to protect 100% of the mice with 10LD50 of H7N9 strain. Cases of H7N9 human infection caused by an avian-origin H...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2020-11, Vol.38 (50), p.7938-7948
Main Authors: Liu, Bo, Shi, Pingping, Wang, Tiantian, Zhao, Yongkun, Lu, Shihao, Li, Xiang, Luo, Shiqiang, Chang, Shaohong, Wang, Sha, Sun, Peng, Gong, Xin, Gao, Yuwei, Wu, Jun
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antibodies, Viral
China
Eggs
Embryos
Epidemics
Fermentation
Glycerol
Glycoproteins
Glycosylation
H7N9
Hemagglutination inhibition
Hemagglutinin Glycoproteins, Influenza Virus - genetics
Hemagglutinins
Influenza
Influenza A Virus, H7N9 Subtype - genetics
Influenza vaccine
Influenza Vaccines
Influenza, Human
Lethal dose
Mice
Nanoparticles
Orthomyxoviridae Infections - prevention & control
Pandemics
Pichia pastoris
Polyethylene glycol
Proteins
rH7
Saccharomycetales
Subunit vaccine
Vaccines
Viruses
Yeast
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The rH7 was expressed successfully in glycoengineered Pichia pastoris system.•The rH7 had complex glycosylation modifications and polymerized to nanoparticles.•The 3.75 µg rH7 was found to protect 100% of the mice with 10LD50 of H7N9 strain. Cases of H7N9 human infection caused by an avian-origin H7N9 virus emerged in eastern China in 2013, leading to the urgent requirement of developing an effective vaccine to reduce its pandemic potential. In this report, the full-length recombinant H7 protein (rH7) of A/Hangzhou/1/2013 (H7N9) virus was expressed by a glycoengineered Pichia pastoris system. The rH7 protein underwent complex glycosylation modifications and polymerized to nanoparticles of 30–50 nm in diameter. Recombinant H7 (1.9 µg) elicited a > 1:40 hemagglutination inhibition titer, and 3.75 µg rH7 protected 100% of the mice in the mice challenge model with 10-fold 50% lethal dose of the A/Shanghai/2/2013 (H7N9) rat lung-adapted strain. In conclusion, rH7 produced by the glycoengineered P. pastoris can be used for vaccination against the H7N9 virus, and provides an effective platform for the rapid production of future influenza vaccines.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2020.10.061